Tarsus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
TARS Tarsus Pharmaceuticals Inc
TXN Texas Instruments Inc
GTH Genetron Holdings Ltd
$NQAT60LMGBPT Nasdaq Austria Energy Large Mid Cap
FICO Fair Isaac Corp
CBDL Cbd Life Sciences Inc
HKXCY Hong Kong Exchanges and Clearing Ltd
TOMZ TOMI Environmental Solutions Inc
GDXD MicroSectors? Gold Miners -3X Inverse Leveraged ETNs
CWK Cushman & Wakefield PLC
Go

Health Care : Pharmaceuticals |
Company profile

Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapeutics. The Company's lead product candidate, TP-03, is an investigational eye drop in Phase III to treat blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. Blepharitis (Blephar is a reference to eyelid and itis is a reference to inflammation) is a condition characterized by inflammation of the eyelid margin, redness and ocular irritation, including a specific type of eyelash dandruff called collarettes, which are pathognomonic for Demodex blepharitis. The Company designed TP-03 to target and eradicate the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of TP-03, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels.

Closing Price
$17.32
Day's Change
-0.23 (-1.31%)
Bid
--
Ask
--
B/A Size
--
Day's High
18.10
Day's Low
17.25
Volume
(Light)
Volume:
57,294

10-day average volume:
74,531
57,294

Company Profile

Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapeutics. The Company's lead product candidate, TP-03, is an investigational eye drop in Phase III to treat blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. Blepharitis (Blephar is a reference to eyelid and itis is a reference to inflammation) is a condition characterized by inflammation of the eyelid margin, redness and ocular irritation, including a specific type of eyelash dandruff called collarettes, which are pathognomonic for Demodex blepharitis. The Company designed TP-03 to target and eradicate the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of TP-03, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
15.12x
Price/Book (MRQ)
2.45x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

July 2022
Current Month
1.3M
Previous Month
1.3M
Percent of Float
7.97%
Days to Cover
17.5961 Days

Share Information

TARS is in a share class of common stock
Float
11.7M
Shares Outstanding
20.7M
Institutions Holding Shares
83
78.86%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Michael Ackermann
  • Bobak AzamianPres.
  • Leo M. GreensteinCFO
  • Seshadri NeervannanCOO
  • Dianne C. Whitfield

Address

Insider Trading

During the most recent quarter, 100K shares were bought, and 518K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.